ITPP (MYO-INOSITOL TRISPYROPHOSPHATE) - 1gr/5gr
New

ITPP (MYO-INOSITOL TRISPYROPHOSPHATE) - 1gr/5gr

€46.00
  • 5 Grams
  • 1 Gram

Myo-Inositol Trispyrophosphate Hexasodium Salt (ITPP) is a compound known for enhancing oxygen delivery to tissues by modifying hemoglobin's oxygen affinity. The result is improved metabolic efficiency and better tissue oxygenation. It also exhibits significant antioxidant and anti-inflammatory properties, and various studies have published very promising results in anti-aging, cancer treatment, and the management of degenerative diseases such as Alzheimer's and Parkinson's.

Description

STRUCTURE

ITPP (Myo-Inositol Trispyrophosphate Hexasodium Salt) 

Molecular Formula: C6H6Na6O21P6

Molecular Weight: 737.88 g/mol

CAS Number: 23103-35-7

Purity: Greater than 99%

Storage Temperature: -20°C


DESCRIPTION

Myo-Inositol Trispyrophosphate Hexasodium Salt, commonly known as ITPP, is a chemical compound that has garnered significant attention in recent years due to its wide range of potential therapeutic applications. ITPP is a derivative of myo-inositol, a carbocyclic sugar that is an important component of cell membrane phospholipids. This compound has shown promise in enhancing oxygen delivery to tissues, providing cardiovascular benefits, exhibiting antioxidant properties, and influencing several metabolic and physiological pathways.

ITPP is a hexasodium salt of myo-inositol trispyrophosphate, which structurally modifies the inositol ring by adding three pyrophosphate groups. This unique structure allows ITPP to interact with hemoglobin and modify its affinity for oxygen. The result is an increased release of oxygen from hemoglobin to the tissues.


Metabolic Effects

ITPP influences several metabolic pathways within the body. By increasing oxygen availability to tissues, it enhances aerobic respiration and energy production. This is particularly beneficial in tissues with high metabolic demands, such as muscles and the brain. Increased oxygen delivery can improve metabolic efficiency and reduce the buildup of lactate during anaerobic metabolism, thus enhancing overall metabolic performance.


Cardiovascular Effects

One of the most significant effects of ITPP is its impact on the cardiovascular system. By facilitating oxygen release from hemoglobin, ITPP improves oxygenation of the myocardium (heart muscle) and other critical tissues. This can lead to improved cardiac function, enhanced exercise tolerance, and reduced symptoms in conditions such as heart failure and ischemic heart disease. Additionally, ITPP has been shown to have vasodilatory effects, which can help lower blood pressure and improve blood flow.


Tissue Oxygenation

The primary function of ITPP is to enhance tissue oxygenation. By decreasing the affinity of hemoglobin for oxygen, ITPP ensures that more oxygen is released into the tissues, especially under hypoxic conditions. This property makes ITPP a potential therapeutic agent for diseases characterized by poor oxygen delivery, such as chronic obstructive pulmonary disease (COPD), peripheral artery disease, and certain forms of anemia.


Antioxidant Properties

ITPP exhibits antioxidant properties by reducing oxidative stress in tissues. Oxidative stress occurs when there is an imbalance between the production of reactive oxygen species (ROS) and the body's ability to detoxify them. By improving oxygen delivery and reducing the need for anaerobic metabolism, ITPP can decrease the production of ROS. This reduction in oxidative stress can protect cells from damage, reduce inflammation, and slow the progression of various chronic diseases.


Mitochondrial Effects

Mitochondria are the powerhouse of cells, responsible for producing the majority of cellular energy through oxidative phosphorylation. By enhancing oxygen delivery to cells, ITPP supports mitochondrial function and efficiency. This can lead to increased ATP production, improved cellular energy levels, and enhanced overall mitochondrial health. These effects are particularly beneficial in tissues with high energy demands, such as muscles and the brain.


Cerebral Effects

The brain is one of the most oxygen-dependent organs in the body. ITPP’s ability to enhance oxygen delivery to the brain can have profound effects on cognitive function, mental clarity, and overall brain health. Improved oxygenation can support neuronal function, protect against neurodegenerative diseases, and enhance recovery from brain injuries. Additionally, the antioxidant properties of ITPP can help protect brain cells from oxidative damage and reduce the risk of conditions like Alzheimer’s disease and Parkinson’s disease.


Immunological Effects

ITPP may also have beneficial effects on the immune system. Enhanced tissue oxygenation can improve the function of immune cells, such as macrophages and lymphocytes, which are critical for defending the body against infections and diseases. By supporting the metabolic needs of these cells, ITPP can enhance the immune response, reduce inflammation, and promote overall immune health.


Anti-Aging Effects

ITPP’s ability to enhance oxygen delivery and reduce oxidative stress can contribute to its anti-aging effects. By improving mitochondrial function, reducing cellular damage, and enhancing overall metabolic efficiency, ITPP can slow down the aging process at the cellular level. These effects can translate to improved skin health, better physical performance, and enhanced overall vitality.


Anti-Inflammatory Effects

ITPP has shown potential in reducing inflammation by decreasing oxidative stress and improving oxygen delivery to tissues. Chronic inflammation is a key factor in many diseases, including autoimmune disorders and chronic infections. By modulating the inflammatory response, ITPP can help manage and reduce symptoms associated with these conditions.


Anticancer Properties

Preliminary studies suggest that ITPP may have anticancer properties. By improving oxygen delivery to tumor tissues, ITPP can inhibit the hypoxic environment that tumors often create to protect themselves from the immune system and conventional therapies. Enhanced oxygenation can increase the effectiveness of radiation therapy and certain chemotherapeutic agents, making cancer cells more susceptible to treatment.


Benefits for Degenerative Diseases

ITPP's potential to improve oxygenation and reduce oxidative stress makes it a promising candidate for treating degenerative diseases. Conditions such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis (ALS) are characterized by progressive neuronal damage and dysfunction. By protecting neurons and supporting their function, ITPP can help slow disease progression and improve quality of life for patients with these conditions.


Additional Benefits

In addition to the effects mentioned above, ITPP has several other potential benefits:

  • Exercise Performance: Athletes may benefit from ITPP due to its ability to improve oxygen delivery to muscles, reduce fatigue, and enhance endurance.
  • Wound Healing: Enhanced oxygenation can accelerate the healing of wounds and improve tissue repair processes.
  • Chronic Conditions: Patients with chronic conditions such as diabetes, chronic kidney disease, and certain types of anemia may find relief from symptoms through improved oxygenation and metabolic support.

REFERENCES

M. Okninska et al., "New potential treatment for cardiovascular disease through modulation of hemoglobin oxygen binding curve: Myo-inositol trispyrophosphate (ITPP), from cancer to cardiovascular disease" [ScienceDirect]

A. Biolo et al., "Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphate" [PubMed]

C. Kieda et al., "Suppression of hypoxia-induced HIF-1α and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes" [PubMed]

G. Sihn et al., "Anti-angiogenic properties of myo-inositol trispyrophosphate in ovo and growth reduction of implanted glioma" [FebsPress]

Ly-Binh-An Tran et al., "Impact of myo-inositol trispyrophosphate (ITPP) on tumour oxygenation and response to irradiation in rodent tumour models" [PubMed]

K.C. Fylaktakidou et al., "Inositol tripyrophosphate: a new membrane permeant allosteric effector of haemoglobin" [PubMed]

M. Bazzano et al., "Respiratory metabolites in bronchoalveolar lavage fluid (BALF) and exhaled breath condensate (EBC) can differentiate horses affected by severe equine asthma from healthy horses" [PubMed]


DISCLAIMER

This product is intendend for lab research and development use only. These studies are performed outside of the body. This product is not medicines or drugs and has not been approved by the FDA or EMA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals.

All product information provided on this website is for informational and educational purposes only.

Data sheet

ITP0105